-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

Benzinga·10/19/2026 12:14:40
Listen to the news
Canaccord Genuity analyst Whitney Ijem initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $18.